Derrell Porter Reduces Stake in ABOS
Derrell Porter sold 13,040 shares of ABOS on June 17, 2026.
Key Points
- Derrell Porter sold 13,040 shares of ABOS on June 17, 2026, with no stated transaction value.
- ABOS shares traded at $2.33 at the time of the transaction, though the exact sale price was not disclosed.
- No additional insider transactions, analyst ratings, or institutional changes were reported for ABOS.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 17, 2026, Derrell Porter sold 13,040 shares of ABOS. The transaction did not specify a sale price, but ABOS shares were trading at $2.33 at the time.
Insider Buying and Selling at Acumen Pharmaceuticals, Inc.
Derrell Porter was involved in a notable transaction involving ABOS, selling 13,040 shares. The sale did not occur under a pre-planned trading scheme, and the transaction code was recorded as 'M'.
Bottom Line
The decision by Derrell Porter to sell shares of ABOS is a point of interest for investors tracking insider activity. While the transaction did not specify a sale price, the stock traded at $2.33. Such insider transactions can provide insights into the sentiment of those closest to the company.
Get Acumen Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ABOS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.